Developer docs
API playgroundTry for free, no card

Search company profiles

Xiangxue Pharmaceutical

Full company profile

uuid003ayhu

Namestring
Xiangxue Pharmaceutical
Legal namestring
广州市香雪制药股份有限公司
Websiteurl
xphcn.com
Company typeenum
Public
Founded yearint
1997
Descriptiontext

Xiangxue Pharmaceutical (广州市香雪制药股份有限公司) is a Chinese pharmaceutical company headquartered in Guangzhou, established in its current corporate form in 1997 (with predecessor Luogang Pharmaceutical Factory dating to 1958), and listed on the Shenzhen Stock Exchange ChiNext board (SZ300147). The company operates three principal business segments: traditional Chinese medicine (TCM) products including Chinese patent medicines (e.g., Antiviral Oral Liquid, Banlangen Granules, Juhong Cough series), TCM resources covering GAP-certified medicinal herb plantations and TCM prescription granules, and biopharmaceuticals centered on TCR-T cell therapy through its wholly-owned subsidiary XLifeSc. It also markets health beverages (Lingcha herbal teas), collagen-based supplements, and medical devices including surgical adhesives and neurosurgical fixation systems.

The company's technology base spans proprietary TCM quality control (China's first fingerprint spectrum QC technology applied to Chinese patent medicines, exceeding Chinese Pharmacopoeia standards, plus a 4C quality management system) and cutting-edge biopharmaceutical capabilities through the TAEST (TCR Affinity Enhanced Specific T-cell Therapy) platform, backed by 150+ international patents and making Xiangxue the second company globally pursuing high-affinity TCR-T gene therapy. Lead candidate TAEST16001 is China's first TCR-T product to receive IND approval, currently in confirmatory clinical trials for soft tissue sarcoma and other NY-ESO-1 positive solid tumors with reported Phase I ORR of 41.7% and Phase II best ORR of 50%. The pipeline also includes TAEST1901 (liver/gastric cancer, IND approved 2022) and XLS-103 (NSCLC/pancreatic cancer, IND approved 2025). Additional technology assets include the Smart TCM platform with AI Four Diagnostic Instrument and IoT-enabled prescription dispensing.

Revenue is generated across multiple streams: OTC consumer products sold through retail pharmacy chains; prescription TCM granules and Chinese patent medicines distributed via hospital and clinical channels; export of TCM products to UK, US, and other markets; health beverages and supplements sold through e-commerce and DTC channels; and, prospectively, licensing/royalty income from TCR-T therapies. Customer segments span end consumers for cold/flu and respiratory products, healthcare providers for TCM prescription products, cancer centers for TCR-T clinical trials, and grassroots community clinics for AI-enabled TCM constitution assessment services. The company maintains a vertically integrated supply chain with GAP plantations across 8+ Chinese provinces, R&D centers in Guangzhou, Beijing, Cambridge UK, and Macau, and 60+ wholly-owned subsidiaries supporting operations from herb cultivation through to finished pharmaceutical products.

Short descriptiontext

Xiangxue Pharmaceutical is a Chinese pharmaceutical company headquartered in Guangzhou that manufactures traditional Chinese medicine products, operates GAP-certified herb plantations, and develops TCR-T cell therapies through its XLifeSc subsidiary for oncology indications.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersGuangzhou, China
HQ citystring
Guangzhou
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices12 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
traditional Chinese medicine, Chinese patent medicines, TCR-T cell therapy, TCM herbal granules, biopharmaceutical R&D
Industry3 codes
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
SECONDARYHLAIAJAO
Compounding Ingredient & API Distributors (Pharma Supply)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
NAICS code4 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Medicinal and Botanical Manufacturing325411
  • Biological Product (except Diagnostic) Manufacturing325414
  • Medical Equipment and Supplies Manufacturing3391
SIC code4 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
  • Biological Products, (No Disgnostic Substances)2836
  • Surgical & Medical Instruments & Apparatus3841
Product category
Traditional Chinese Medicine
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model6 records
1中成药及配方颗粒
TypeOne Time License
Description

香雪制药的核心业务板块,包括抗病毒口服液、橘红痰咳液、板蓝根颗粒、夏桑菊颗粒等中成药产品,以及中药配方颗粒的生产和销售

xphcn.com
2中药饮片
TypeOne Time License
Description

以化橘红为核心的岭南道地中药饮片,包括化橘红、化橘红胎、化橘红丝饮片等,被评为广东省非物质文化遗产

xphcn.com
3大健康产品
TypeOne Time License
Description

包括上清饮凉茶、湿湿碎凉茶、胶原蛋白肽果蔬纤维固体饮料等健康饮品和保健品,满足大众健康消费需求

xphcn.com
4TCR-T细胞治疗产品
TypeLicensing Royalties
Description

香雪生命科学专注于TCR-T肿瘤免疫治疗产品研发,TAEST16001已进入确证性临床试验,有望成为国内首个上市的TCR-T产品

xphcn.com
5医疗器械
TypeHardware Sales
Description

包括医用创面封闭型、吻合型、EC型、ZT型等医用粘合剂产品

xphcn.com
6中药资源供应
TypeOne Time License
Description

在全国多地建立GAP种植基地和GMP生产基地,构建覆盖中药资源开发、精深加工的产业链

xphcn.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1香雪生命科学 (XLifeSc)
Description

TCR-T细胞免疫治疗产品和技术的研发企业,国内TCR-T细胞免疫治疗的头部企业

xphcn.com
+4 more records
Core offering1 text field

Xiangxue Pharmaceutical develops, manufactures, and sells Chinese patent medicines, traditional Chinese medicine (TCM) raw materials and formula granules, and biopharmaceutical products, with a strategic research focus on TCR-T cell therapy. Its products serve both medical institutions (prescription and clinical trial supply) and retail/consumer channels (OTC medicines, health beverages, and herbal tea), with manufacturing and QC operations in Guangzhou and supporting subsidiaries across Guangdong, Sichuan, Yunnan, and other provinces.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • TAEST16001 I期临床试验客观缓解率(ORR)达到41.7%,疾病控制率83.3%
+3 more records
Product overview1 text field

Xiangxue Pharmaceutical operates as a diversified traditional Chinese medicine (TCM) and biopharmaceutical company with three main business segments: 1) Pharmaceutical products including Chinese patent medicines (中成药) such as Antiviral Oral Liquid, Juhong Cough series, Banlangen Granules, and other TCM formulations; 2) Traditional Chinese Medicine resources including medicinal herbs, herbal slices, and GAP-certified raw materials from Huazhou Citri Grandis and other geo-authentic sources; 3) Biopharmaceuticals focused on TCR-T cell therapy products developed by subsidiary XLifeSc. The company also offers health beverages (上清饮凉茶, 湿湿碎凉茶), health supplements (胶原蛋白肽饮料 series), and medical devices (surgical adhesives, brain fixation systems). Digital capabilities include the 香雪智慧中医 platform integrating AI-powered four-diagnostic instruments for TCM constitution assessment and community health services.

Product and service4 records
1Chinese Patent Medicines (中成药)
CategoryPrescription & OTC Chinese Patent Medicine
Description

Branded and generic Chinese patent medicines (oral liquids, capsules, granules, etc.) developed in-house and sold through hospital pharmacy channels and retail pharmacy chains; the company's longest-standing commercial offering.

2TCM Resources — Raw Materials and Formula Granules (中药资源 / 配方颗粒)
CategoryTCM Raw Materials and Formula Granules
Description

Standardized TCM herbal raw materials and formula granules produced under fingerprint quality control, supplied to the company's own manufacturing lines, to hospital centralized decoction rooms, and to other pharmaceutical manufacturers.

3XLifeSc TCR-T Cell Therapy Pipeline (香雪生命科学 TCR-T 细胞疗法)
CategoryBiopharmaceuticals / Cell Therapy
Description

Investigational TCR-T cell therapy products for solid tumors, developed and advanced toward clinical trials by the Xiangxue Life Science subsidiary; aimed at hospital oncology departments and clinical trial sites.

4Xiangxue Herbal Health Beverages (香雪凉茶等大健康产品)
CategoryConsumer Health Beverages
Description

Branded herbal health beverages and packaged TCM-derived drinks sold through self-operated e-commerce stores, distributor channels, and direct-to-consumer lifestyle events as part of the company's "big health" consumer line.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-09-01
Description

北京大学肿瘤医院作为TAEST16001 II期临床试验的参与中心,共同推进TCR-T细胞治疗的临床研究。

2Athenex Inc.
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-12-17
Description

香雪制药与Athenex扩大战略合作,获得口服紫杉醇、口服伊立替康和Tirbanibulin软膏在中国开发和商业化的独家权利,交易总金额可能达到2亿美元(不含特许权使用费)。此次合作拓展了香雪的新药产品线,包括两个积极的III期临床试验产品和一个准备进入II期的概念验证数据产品。

xphcn.com
3澳门大学
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-06-26
Description

香雪与澳门大学合作建设大湾区中医药国际创新平台及智慧中医产业化示范基地,在澳门及广州建立智慧中医平台及中医社区服务网络,为大湾区提供优质中医药服务。

xphcn.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2018-03-01
Description

香雪与GE医疗正式启动建设细胞治疗产业化区域制备平台和临床转化中心的项目,提升细胞治疗产品的产业化能力。

5中山大学肿瘤防治中心
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

中山大学肿瘤防治中心作为TAEST16001 TCR-T细胞治疗I期和II期临床试验的牵头研究中心,与香雪生命科学开展深度临床研究合作。

xphcn.com
6Athenex/Axis Therapeutics
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

香雪生命科学授权Athenex/ Axis Therapeutics在除中国大陆以外的地区研发、商业化TAEST16001 TCR-T疗法。Axis Therapeutics的TCR-T细胞疗法IND获得美国FDA批准进入临床试验。

xphcn.com
7南方医科大学南方医院
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

香雪与南方医科大学南方医院合作建立精准医学中心,推动精准医疗技术的临床应用。

xphcn.com
8中国科学院广州生物医药与健康研究院(GIBH)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

香雪与中国科学院(GIBH)合建粤港澳干细胞中心,推动干细胞和再生医学研究。

xphcn.com
9杜德生物
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

香雪与杜德生物合作启动全球细胞银行项目,成为国内唯一一家拥有国家级批文和授权资质承接国家组织工程种子细胞库的单位的合作。

xphcn.com
10苏州圣诺生物医药/美国Sirnaomics
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2010-01-01
Description

香雪与苏州圣诺生物医药、美国Sirnaomics合作新药创制项目STP705,该项目获得CFDA临床批件,成为中国首个小核酸药物。

xphcn.com
11英国Phynova
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2009-01-01
Description

香雪与英国Phynova合作开发植物药,治疗关节痛及感冒的药品于2015年、2017年先后获得英国MHRA注册批准,开创中药产品在英国上市的先河。

xphcn.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers9 records
TypeOthers
Description

Adjacent peer operating TCM telemedicine and AI-assisted TCM diagnosis services. Comparable to Xiangxue's Xiangxue Wisdom TCM platform effort to digitize and scale grassroots TCM delivery in China.

TypeEmerging player
Description

Chinese cell therapy company (CAR-T focused, with TCR pipeline) that pioneered the first CAR-T approval in China. Competes directly with Xiangxue's TCR-T platform in the engineered T-cell therapy space with greater clinical experience.

3Athenex Inc.
TypeOthers
Description

Strategic partner of Xiangxue for oncology pipeline development (oral paclitaxel, oral irinotecan, tirbanibulin) and TCR-T licensing ex-China. Provides access to Xiangxue's TCR-T platform and oral chemotherapy assets.

4Guangzhou Baiyunshan Pharmaceutical Holdings
TypeRegional player
Description

Largest Guangdong-based pharma conglomerate with extensive TCM portfolio (including established cough/cold brands), strong distribution networks, and substantial R&D. Direct regional competitor in Guangdong and major national TCM markets.

5Beijing Tongrentang Group
TypeBroad incumbent
Description

Most prestigious Chinese TCM brand with royal heritage, focused on premium TCM finished products and clinic services. Competes in the same branded Chinese patent medicine category with broader geographic and brand reach.

TypeDirect peer
Description

Global leader in TCR-T cell therapy with SPEAR T-cell platform, partnered with Athenex/Axis Therapeutics on TAEST16001 ex-China development. Closest international peer in the TCR-T mechanism Xiangxue is pursuing.

7Carsgen Therapeutics
TypeEmerging player
Description

Chinese cell therapy company focused on CAR-T for solid tumors and hematologic malignancies. Competes with Xiangxue's TAEST platform in solid tumor cell therapy with similar targets (Claudin18.2, GPC3) and broader pipeline.

8Yunnan Baiyao Group
TypeBroad incumbent
Description

Largest Chinese TCM conglomerate with diversified portfolio including proprietary products, Chinese medicine resources, and pharma distribution. Direct competitor in branded TCM consumer market and overlapping TCM resource supply chain.

9CR Sanjiu Medical & Pharmaceutical
TypeDirect peer
Description

State-backed TCM specialist under China Resources with overlapping product categories in cold/flu treatments, cough remedies, and TCM finished formulations. Direct competitor in OTC retail channels and hospital prescription TCM market.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries10 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance11 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Xiangxue Pharmaceutical

Traditional Chinese Medicinexphcn.com

Xiangxue Pharmaceutical is a Chinese pharmaceutical company headquartered in Guangzhou that manufactures traditional Chinese medicine products, operates GAP-certified herb plantations, and develops TCR-T cell therapies through its XLifeSc subsidiary for oncology indications.

What Xiangxue Pharmaceutical does

Xiangxue Pharmaceutical (广州市香雪制药股份有限公司) is a Chinese pharmaceutical company headquartered in Guangzhou, established in its current corporate form in 1997 (with predecessor Luogang Pharmaceutical Factory dating to 1958), and listed on the Shenzhen Stock Exchange ChiNext board (SZ300147). The company operates three principal business segments: traditional Chinese medicine (TCM) products including Chinese patent medicines (e.g., Antiviral Oral Liquid, Banlangen Granules, Juhong Cough series), TCM resources covering GAP-certified medicinal herb plantations and TCM prescription granules, and biopharmaceuticals centered on TCR-T cell therapy through its wholly-owned subsidiary XLifeSc. It also markets health beverages (Lingcha herbal teas), collagen-based supplements, and medical devices including surgical adhesives and neurosurgical fixation systems.

The company's technology base spans proprietary TCM quality control (China's first fingerprint spectrum QC technology applied to Chinese patent medicines, exceeding Chinese Pharmacopoeia standards, plus a 4C quality management system) and cutting-edge biopharmaceutical capabilities through the TAEST (TCR Affinity Enhanced Specific T-cell Therapy) platform, backed by 150+ international patents and making Xiangxue the second company globally pursuing high-affinity TCR-T gene therapy. Lead candidate TAEST16001 is China's first TCR-T product to receive IND approval, currently in confirmatory clinical trials for soft tissue sarcoma and other NY-ESO-1 positive solid tumors with reported Phase I ORR of 41.7% and Phase II best ORR of 50%. The pipeline also includes TAEST1901 (liver/gastric cancer, IND approved 2022) and XLS-103 (NSCLC/pancreatic cancer, IND approved 2025). Additional technology assets include the Smart TCM platform with AI Four Diagnostic Instrument and IoT-enabled prescription dispensing.

Revenue is generated across multiple streams: OTC consumer products sold through retail pharmacy chains; prescription TCM granules and Chinese patent medicines distributed via hospital and clinical channels; export of TCM products to UK, US, and other markets; health beverages and supplements sold through e-commerce and DTC channels; and, prospectively, licensing/royalty income from TCR-T therapies. Customer segments span end consumers for cold/flu and respiratory products, healthcare providers for TCM prescription products, cancer centers for TCR-T clinical trials, and grassroots community clinics for AI-enabled TCM constitution assessment services. The company maintains a vertically integrated supply chain with GAP plantations across 8+ Chinese provinces, R&D centers in Guangzhou, Beijing, Cambridge UK, and Macau, and 60+ wholly-owned subsidiaries supporting operations from herb cultivation through to finished pharmaceutical products.

Xiangxue Pharmaceutical firmographics

Firmographics
Name
Xiangxue Pharmaceutical
Legal name
广州市香雪制药股份有限公司
Website
https://xphcn.com
Company type
Public
Founded year
1997
Operating status
Operating
Headcount range
101–250 employees
Short description
Xiangxue Pharmaceutical is a Chinese pharmaceutical company headquartered in Guangzhou that manufactures traditional Chinese medicine products, operates GAP-certified herb plantations, and develops TCR-T cell therapies through its XLifeSc subsidiary for oncology indications.
Ownership category
akta.pro rank

Xiangxue Pharmaceutical industry classification

Industry
Product category
Traditional Chinese Medicine
NAICS
Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Biological Product (except Diagnostic) Manufacturing (325414), Medical Equipment and Supplies Manufacturing (3391)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
SECONDARYHLAIAJAO
Compounding Ingredient & API Distributors (Pharma Supply)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling

Keywords

  • Traditional Chinese medicine
  • Chinese patent medicines
  • TCR-T cell therapy
  • TCM herbal granules
  • Biopharmaceutical R&D

Where Xiangxue Pharmaceutical is headquartered

Location

Headquarters

HQ city
Guangzhou
HQ country
China
HQ region
Asia

Offices12 records

Markets served

Xiangxue Pharmaceutical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. 中成药及配方颗粒: 香雪制药的核心业务板块,包括抗病毒口服液、橘红痰咳液、板蓝根颗粒、夏桑菊颗粒等中成药产品,以及中药配方颗粒的生产和销售
  2. 中药饮片: 以化橘红为核心的岭南道地中药饮片,包括化橘红、化橘红胎、化橘红丝饮片等,被评为广东省非物质文化遗产
  3. 大健康产品: 包括上清饮凉茶、湿湿碎凉茶、胶原蛋白肽果蔬纤维固体饮料等健康饮品和保健品,满足大众健康消费需求
  4. TCR-T细胞治疗产品: 香雪生命科学专注于TCR-T肿瘤免疫治疗产品研发,TAEST16001已进入确证性临床试验,有望成为国内首个上市的TCR-T产品
  5. 医疗器械: 包括医用创面封闭型、吻合型、EC型、ZT型等医用粘合剂产品
  6. 中药资源供应: 在全国多地建立GAP种植基地和GMP生产基地,构建覆盖中药资源开发、精深加工的产业链

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Xiangxue Pharmaceutical product offering

Product offering

Core offering

Xiangxue Pharmaceutical develops, manufactures, and sells Chinese patent medicines, traditional Chinese medicine (TCM) raw materials and formula granules, and biopharmaceutical products, with a strategic research focus on TCR-T cell therapy. Its products serve both medical institutions (prescription and clinical trial supply) and retail/consumer channels (OTC medicines, health beverages, and herbal tea), with manufacturing and QC operations in Guangzhou and supporting subsidiaries across Guangdong, Sichuan, Yunnan, and other provinces.

Product overview

Xiangxue Pharmaceutical operates as a diversified traditional Chinese medicine (TCM) and biopharmaceutical company with three main business segments: 1) Pharmaceutical products including Chinese patent medicines (中成药) such as Antiviral Oral Liquid, Juhong Cough series, Banlangen Granules, and other TCM formulations; 2) Traditional Chinese Medicine resources including medicinal herbs, herbal slices, and GAP-certified raw materials from Huazhou Citri Grandis and other geo-authentic sources; 3) Biopharmaceuticals focused on TCR-T cell therapy products developed by subsidiary XLifeSc. The company also offers health beverages (上清饮凉茶, 湿湿碎凉茶), health supplements (胶原蛋白肽饮料 series), and medical devices (surgical adhesives, brain fixation systems). Digital capabilities include the 香雪智慧中医 platform integrating AI-powered four-diagnostic instruments for TCM constitution assessment and community health services.

Differentiator

Problem solved

Functional benefit

Brands

  • 香雪生命科学 (XLifeSc): TCR-T细胞免疫治疗产品和技术的研发企业,国内TCR-T细胞免疫治疗的头部企业
  • 香雪智慧中医
  • 广东省凉茶博物馆
  • TAEST
  • 香雪抗病毒口服液

Products and services

  • Chinese Patent Medicines (中成药) Branded and generic Chinese patent medicines (oral liquids, capsules, granules, etc.) developed in-house and sold through hospital pharmacy channels and retail pharmacy chains; the company's longest-standing commercial offering.
  • TCM Resources — Raw Materials and Formula Granules (中药资源 / 配方颗粒) Standardized TCM herbal raw materials and formula granules produced under fingerprint quality control, supplied to the company's own manufacturing lines, to hospital centralized decoction rooms, and to other pharmaceutical manufacturers.
  • XLifeSc TCR-T Cell Therapy Pipeline (香雪生命科学 TCR-T 细胞疗法) Investigational TCR-T cell therapy products for solid tumors, developed and advanced toward clinical trials by the Xiangxue Life Science subsidiary; aimed at hospital oncology departments and clinical trial sites.
  • Xiangxue Herbal Health Beverages (香雪凉茶等大健康产品) Branded herbal health beverages and packaged TCM-derived drinks sold through self-operated e-commerce stores, distributor channels, and direct-to-consumer lifestyle events as part of the company's "big health" consumer line.

Quantifiable outcome

  • TAEST16001 I期临床试验客观缓解率(ORR)达到41.7%,疾病控制率83.3%
  • +3 more outcomes

Companies that use Xiangxue Pharmaceutical

Customer profile

Named customers6 records

Segments6 records

Ideal customer profiles3 records

Xiangxue Pharmaceutical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature6 records

Xiangxue Pharmaceutical partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core and minor.

  • 北京大学肿瘤医院coreStrategic or Co-development Partner · 1 September 2022北京大学肿瘤医院作为TAEST16001 II期临床试验的参与中心,共同推进TCR-T细胞治疗的临床研究。
  • Athenex Inc.coreStrategic or Co-development Partner · 17 December 2019香雪制药与Athenex扩大战略合作,获得口服紫杉醇、口服伊立替康和Tirbanibulin软膏在中国开发和商业化的独家权利,交易总金额可能达到2亿美元(不含特许权使用费)。此次合作拓展了香雪的新药产品线,包括两个积极的III期临床试验产品和一个准备进入II期的概念验证数据产品。
  • 澳门大学coreStrategic or Co-development Partner · 26 June 2019香雪与澳门大学合作建设大湾区中医药国际创新平台及智慧中医产业化示范基地,在澳门及广州建立智慧中医平台及中医社区服务网络,为大湾区提供优质中医药服务。
  • GE医疗coreTechnology or Integration · 1 March 2018香雪与GE医疗正式启动建设细胞治疗产业化区域制备平台和临床转化中心的项目,提升细胞治疗产品的产业化能力。
  • 中山大学肿瘤防治中心coreStrategic or Co-development Partner · 1 January 2018中山大学肿瘤防治中心作为TAEST16001 TCR-T细胞治疗I期和II期临床试验的牵头研究中心,与香雪生命科学开展深度临床研究合作。
  • Athenex/Axis TherapeuticscoreStrategic or Co-development Partner · 1 January 2018香雪生命科学授权Athenex/ Axis Therapeutics在除中国大陆以外的地区研发、商业化TAEST16001 TCR-T疗法。Axis Therapeutics的TCR-T细胞疗法IND获得美国FDA批准进入临床试验。
  • 南方医科大学南方医院minorStrategic or Co-development Partner · 1 January 2018香雪与南方医科大学南方医院合作建立精准医学中心,推动精准医疗技术的临床应用。
  • 中国科学院广州生物医药与健康研究院(GIBH)coreStrategic or Co-development Partner · 1 January 2018香雪与中国科学院(GIBH)合建粤港澳干细胞中心,推动干细胞和再生医学研究。
  • 杜德生物minorStrategic or Co-development Partner · 1 January 2018香雪与杜德生物合作启动全球细胞银行项目,成为国内唯一一家拥有国家级批文和授权资质承接国家组织工程种子细胞库的单位的合作。
  • 苏州圣诺生物医药/美国SirnaomicscoreStrategic or Co-development Partner · 1 January 2010香雪与苏州圣诺生物医药、美国Sirnaomics合作新药创制项目STP705,该项目获得CFDA临床批件,成为中国首个小核酸药物。
  • 英国PhynovaminorStrategic or Co-development Partner · 1 January 2009香雪与英国Phynova合作开发植物药,治疗关节痛及感冒的药品于2015年、2017年先后获得英国MHRA注册批准,开创中药产品在英国上市的先河。

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Xiangxue Pharmaceutical competitors and assessment

Company assessment

Others

  • Ping An Healthcare and Technology: Adjacent peer operating TCM telemedicine and AI-assisted TCM diagnosis services. Comparable to Xiangxue's Xiangxue Wisdom TCM platform effort to digitize and scale grassroots TCM delivery in China.
  • Athenex Inc. Strategic partner of Xiangxue for oncology pipeline development (oral paclitaxel, oral irinotecan, tirbanibulin) and TCR-T licensing ex-China. Provides access to Xiangxue's TCR-T platform and oral chemotherapy assets.

Emerging players

  • JW Therapeutics: Chinese cell therapy company (CAR-T focused, with TCR pipeline) that pioneered the first CAR-T approval in China. Competes directly with Xiangxue's TCR-T platform in the engineered T-cell therapy space with greater clinical experience.
  • Carsgen Therapeutics: Chinese cell therapy company focused on CAR-T for solid tumors and hematologic malignancies. Competes with Xiangxue's TAEST platform in solid tumor cell therapy with similar targets (Claudin18.2, GPC3) and broader pipeline.

Regional players

  • Guangzhou Baiyunshan Pharmaceutical Holdings: Largest Guangdong-based pharma conglomerate with extensive TCM portfolio (including established cough/cold brands), strong distribution networks, and substantial R&D. Direct regional competitor in Guangdong and major national TCM markets.

Broad incumbents

  • Beijing Tongrentang Group: Most prestigious Chinese TCM brand with royal heritage, focused on premium TCM finished products and clinic services. Competes in the same branded Chinese patent medicine category with broader geographic and brand reach.
  • Yunnan Baiyao Group: Largest Chinese TCM conglomerate with diversified portfolio including proprietary products, Chinese medicine resources, and pharma distribution. Direct competitor in branded TCM consumer market and overlapping TCM resource supply chain.

Direct peers

  • Adaptimmune Therapeutics: Global leader in TCR-T cell therapy with SPEAR T-cell platform, partnered with Athenex/Axis Therapeutics on TAEST16001 ex-China development. Closest international peer in the TCR-T mechanism Xiangxue is pursuing.
  • CR Sanjiu Medical & Pharmaceutical: State-backed TCM specialist under China Resources with overlapping product categories in cold/flu treatments, cough remedies, and TCM finished formulations. Direct competitor in OTC retail channels and hospital prescription TCM market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Xiangxue Pharmaceutical social profiles

Digital presence

Xiangxue Pharmaceutical compliance and trust

Trust signal

Compliance11 records

Xiangxue Pharmaceutical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Xiangxue Pharmaceutical leadership team

Management profile

Number of profiles

Profiles1 record

Xiangxue Pharmaceutical subsidiaries and ownership

Company hierarchy

Subsidiaries10 records

Xiangxue Pharmaceutical funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Xiangxue Pharmaceutical M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Xiangxue Pharmaceutical

What does Xiangxue Pharmaceutical do?

Xiangxue Pharmaceutical develops, manufactures, and sells Chinese patent medicines, traditional Chinese medicine (TCM) raw materials and formula granules, and biopharmaceutical products, with a strategic research focus on TCR-T cell therapy. Its products serve both medical institutions (prescription and clinical trial supply) and retail/consumer channels (OTC medicines, health beverages, and herbal tea), with manufacturing and QC operations in Guangzhou and supporting subsidiaries across Guangdong, Sichuan, Yunnan, and other provinces.

Is Xiangxue Pharmaceutical a public or private company?

Xiangxue Pharmaceutical is a public company. It is classified as public and is currently operating.

When was Xiangxue Pharmaceutical founded?

Xiangxue Pharmaceutical was founded in 1997. It employs 101 to 250 people.

Where is Xiangxue Pharmaceutical based?

Xiangxue Pharmaceutical is headquartered in Guangzhou, China, in the Asia region.

How does Xiangxue Pharmaceutical make money?

Six revenue lines are on record. 中成药及配方颗粒 is the primary driver. The others are 中药饮片, 大健康产品, TCR-T细胞治疗产品, 医疗器械 and 中药资源供应.

Who are Xiangxue Pharmaceutical's main competitors?

Others on record are Ping An Healthcare and Technology and Athenex Inc.. Emerging players are JW Therapeutics and Carsgen Therapeutics. Guangzhou Baiyunshan Pharmaceutical Holdings is listed as a regional player. Broad incumbents are Beijing Tongrentang Group and Yunnan Baiyao Group. Direct peers are Adaptimmune Therapeutics and CR Sanjiu Medical & Pharmaceutical.

Does Xiangxue Pharmaceutical have an API?

No public API is recorded for Xiangxue Pharmaceutical.

What industry is Xiangxue Pharmaceutical in?

Xiangxue Pharmaceutical's product category is Traditional Chinese Medicine. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIABAI, Contract Development & Manufacturing for Generics (CDMO/CMO). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswirePolyU - Axis Therapeutics Joint Center for Immunotherapy Launched to Develop Innovative Cancer TreatmentsThe Hong Kong Polytechnic University (PolyU) has partnered with Axis Therapeutics, a newly established joint venture formed by biopharmaceutical companies Athenex, Inc. and Xiangxue Pharmaceutical, to launch a Joint Center for Immunotherapy focused on developing innovative cancer treatments through TCR-T and CAR-T immunotherapy technologies. The center will leverage Xiangxue Life Sciences' novel high-affinity TCR platform, with an aim to advance treatments for solid tumors. PolyU noted this collaboration contributes to its biotechnology development efforts in the Guangdong-Hong Kong-Macau Greater Bay Area, building on its track record in translational medicine research.PR NewswirePolyU - Axis Therapeutics Joint Center for Immunotherapy Launched to Develop Innovative Cancer TreatmentsThe Hong Kong Polytechnic University (PolyU) and Axis Therapeutics, a joint venture between Athenex, Inc. and Xiangxue Pharmaceutical, signed a memorandum of understanding on July 18, 2018 to establish the PolyU-Axis Therapeutics Joint Center for Immunotherapy. The center will focus on developing TCR-T and CAR-T based cancer immunotherapy technologies using a novel high-affinity TCR approach, with the goal of creating new treatments for solid tumors. The collaboration is positioned within the Guangdong-Hong Kong-Macau Greater Bay Area's biotechnology development strategy, leveraging PolyU's academic capabilities and the companies' pharmaceutical expertise.PR NewswireAthenex announces Xiangxue Pharmaceuticals Company Limited, its KX-02 development partner in China, has achieved a regulatory milestone in that territoryAthenex announced that its Chinese development partner Xiangxue Pharmaceuticals has received completion declaration from the Guangdong Province Food and Drug Administration for the Investigational New Drug (IND) application for KX-02, a novel cancer drug candidate, referring it to the Center of Drug Evaluation of China FDA for review. The IND application was jointly submitted by Xiangxue New Drug Development Company Limited, Xiangxue Pharmaceuticals Limited, and Hangzhou Converd Co., Ltd. under application number CXHL1600187, marking a regulatory milestone in the greater China territory under a 2012 license agreement.